A Major Milestone in Cancer Research BioInvent International AB recently announced a significant breakthrough in oncology: the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to their investigational drug candidate, BI-1808. This development marks a hopeful step forward for patients battling ovarian cancer. What is BI-1808? BI-1808 is a specialized monoclonal antibody…